

# Shinya Kimura

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8003149/publications.pdf>

Version: 2024-02-01

209  
papers

3,134  
citations

236925

25  
h-index

206112

48  
g-index

220  
all docs

220  
docs citations

220  
times ranked

4501  
citing authors

#	ARTICLE	IF	CITATIONS
1	Clonality of HIV-1 and HTLV-1 Infected Cells in Naturally Coinfected Individuals. <i>Journal of Infectious Diseases</i> , 2022, 225, 317-326.	4.0	3
2	Prognostic impact of CEBPA bZIP domain mutation in acute myeloid leukemia. <i>Blood Advances</i> , 2022, 6, 238-247.	5.2	61
3	Non-valvular Infective Endocarditis Caused by <i>Sarocladium kiliense</i> in an Immunocompromised Patient with Aplastic Anemia. <i>Internal Medicine</i> , 2022, 61, 1279-1283.	0.7	3
4	Integrated approach to functional analysis of an ERBB2 variant of unknown significance detected by a cancer gene panel test. <i>Cellular Oncology (Dordrecht)</i> , 2022, 45, 121.	4.4	1
5	Expression level of BTN3A1 on the surface of CD14+ monocytes is a potential predictor of T cell expansion efficiency. <i>Biochemical and Biophysical Research Communications</i> , 2022, 588, 47-54.	2.1	2
6	Targeting DNMT1 by demethylating agent OR-2100 increases tyrosine kinase inhibitors-sensitivity and depletes leukemic stem cells in chronic myeloid leukemia. <i>Cancer Letters</i> , 2022, 526, 273-283.	7.2	9
7	Anti-IL-5 Agents for the Treatment of Idiopathic Chronic Eosinophilic Pneumonia: A Case Series. <i>Journal of Asthma and Allergy</i> , 2022, Volume 15, 169-177.	3.4	7
8	Association of orexin receptor antagonists with falls during hospitalization. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2022, 47, 809-813.	1.5	10
9	NPM1-mutation-based measurable residual disease assessment after completion of two courses of post-remission therapy is a valuable clinical predictor of the prognosis of acute myeloid leukemia. <i>International Journal of Hematology</i> , 2022, , 1.	1.6	2
10	RUNX1 transactivates BCR-ABL expression in Philadelphia chromosome positive acute lymphoblastic leukemia. <i>Cancer Science</i> , 2022, 113, 529-539.	3.9	5
11	Adult T-cell leukemia-lymphoma acquires resistance to DNA demethylating agents through dysregulation of enzymes involved in pyrimidine metabolism. <i>International Journal of Cancer</i> , 2022, 150, 1184-1197.	5.1	5
12	Clinical Implications of Determining Individualized Positive End-Expiratory Pressure Using Electrical Impedance Tomography in Post-Cardiac Surgery Patients: A Prospective, Non-Randomized Interventional Study. <i>Journal of Clinical Medicine</i> , 2022, 11, 3022.	2.4	3
13	Monitoring of tumor cells by flow cytometry permits rapid evaluation of disease progression in monomorphic epitheliotropic intestinal T-cell lymphoma. <i>Cytometry Part B - Clinical Cytometry</i> , 2021, 100, 454-456.	1.5	2
14	HLA Polymorphisms Are Associated with Treatment-Free Remission Following Discontinuation of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia. <i>Molecular Cancer Therapeutics</i> , 2021, 20, 142-149.	4.1	14
15	Evaluation of olfactory dysfunction to estimate the presence of eosinophilic chronic rhinosinusitis in patients with asthma. <i>Respiratory Investigation</i> , 2021, 59, 126-134.	1.8	5
16	Efficacy of dupilumab and biomarkers for systemic corticosteroid naïve allergic bronchopulmonary mycosis. <i>Allergy International</i> , 2021, 70, 145-147.	3.3	5
17	Development of Acquired Hemophilia A After Treatment of Bronchial Asthma with Benralizumab. <i>Indian Journal of Hematology and Blood Transfusion</i> , 2021, 37, 509-510.	0.6	1
18	Ibrutinib-Induced Cardiac Tamponade in Chronic Lymphocytic Leukemia. <i>Turkish Journal of Haematology</i> , 2021, 38, 83-85.	0.5	4

#	ARTICLE	IF	CITATIONS
19	Evolution of CML treatment. <i>International Journal of Hematology</i> , 2021, 113, 622-623.	1.6	1
20	Acute Generalized Exanthematous Pustulosis Caused by Erlotinib in a Patient with Lung Cancer. <i>Case Reports in Oncology</i> , 2021, 14, 599-603.	0.7	5
21	Clinical Manifestations of Allergic Bronchopulmonary Aspergillosis without Major Features of Asthma Diagnosed by the New Criteria in Japan. <i>Internal Medicine</i> , 2021, 60, 1251-1255.	0.7	2
22	A Low Body Mass Index Is Associated with Unsuccessful Treatment in Patients with <i>Mycobacterium avium</i> Complex Pulmonary Disease. <i>Journal of Clinical Medicine</i> , 2021, 10, 1576.	2.4	5
23	Efficacy and safety of ponatinib for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: a case series from a single institute. <i>International Journal of Hematology</i> , 2021, 114, 199-204.	1.6	5
24	Silylation of deoxynucleotide analog yields an orally available drug with anti-leukemia effects. <i>Molecular Cancer Therapeutics</i> , 2021, 20, molcanther.1125.2020.	4.1	6
25	Prolonged gastric mucosal haemorrhage following azacitidine administration in a patient with myelodysplastic syndrome. <i>EJHaem</i> , 2021, 2, 653-654.	1.0	0
26	Aplastic Anemia in a Patient with Cronkhite-Canada Syndrome. <i>Internal Medicine</i> , 2021, 60, 1601-1605.	0.7	3
27	Subsequent attempt tyrosine kinase inhibitor discontinuation in patients with chronic myeloid leukemia; a single institute experience. <i>Hematological Oncology</i> , 2021, 39, 549-557.	1.7	9
28	Skeletal muscle is associated with exercise tolerance evaluated by cardiopulmonary exercise testing in Japanese patients with chronic obstructive pulmonary disease. <i>Scientific Reports</i> , 2021, 11, 15862.	3.3	7
29	Pharmacological MEK inhibition promotes polyclonal T-cell reconstitution and suppresses xenogeneic GVHD. <i>Cellular Immunology</i> , 2021, 367, 104410.	3.0	3
30	Immune Thrombocytopenia Exacerbation After COVID-19 Vaccination in a Young Woman. <i>Cureus</i> , 2021, 13, e17942.	0.5	2
31	Human V $\beta$ 9V $\alpha$ 2 T cells exert anti-tumor activity independently of PD-L1 expression in tumor cells. <i>Biochemical and Biophysical Research Communications</i> , 2021, 573, 132-139.	2.1	16
32	Development of a Competitive Enzyme-Linked Immunosorbent Assay for the Determination of Sunitinib Unaffected by Light-Induced Isomerization. <i>Biological and Pharmaceutical Bulletin</i> , 2021, 44, 1565-1570.	1.4	5
33	Idiopathic eosinophilic pleurisy: A practical diagnostic approach. <i>Respiratory Medicine Case Reports</i> , 2021, 33, 101430.	0.4	1
34	Severity of constipation related to palonosetron during first-line chemotherapy: a retrospective observational study. <i>Supportive Care in Cancer</i> , 2021, 29, 4723-4732.	2.2	2
35	Folic Acid-Appended Hydroxypropyl- $\beta$ -Cyclodextrin Exhibits Potent Antitumor Activity in Chronic Myeloid Leukemia Cells via Autophagic Cell Death. <i>Cancers</i> , 2021, 13, 5413.	3.7	8
36	Statins Enhance the Molecular Response in Chronic Myeloid Leukemia when Combined with Tyrosine Kinase Inhibitors. <i>Cancers</i> , 2021, 13, 5543.	3.7	9

#	ARTICLE	IF	CITATIONS
37	A 45-Year-Old Man With Acute Chest Pain, Fever, and Dyspnea After Tooth Extraction. <i>Chest</i> , 2021, 160, e623-e628.	0.8	0
38	Case Report: Infusion-Related Reactions to Intravenous Infliximab and Subcutaneous Ustekinumab in Pediatric Crohn's Disease. <i>Frontiers in Pediatrics</i> , 2021, 9, 670703.	1.9	1
39	Factors Associated with Reduction of Sedentary Time Following Tiotropium/Olodaterol Therapy in Treatment-Naïve Chronic Obstructive Pulmonary Disease. <i>International Journal of COPD</i> , 2021, Volume 16, 3297-3307.	2.3	3
40	Low-dose dasatinib in older patients with chronic myeloid leukaemia in chronic phase (DAVLEC): a single-arm, multicentre, phase 2 trial. <i>Lancet Haematology</i> , 2021, 8, e902-e911.	4.6	30
41	Naked antisense double-stranded DNA oligonucleotide efficiently suppresses BCR-ABL positive leukemic cells. <i>Investigational New Drugs</i> , 2020, 38, 1012-1019.	2.6	5
42	Epstein-Barr virus-positive diffuse large B cell lymphoma, not otherwise specified, carrying a t(19;22)(q13;q11) translocation. <i>Annals of Hematology</i> , 2020, 99, 389-390.	1.8	0
43	Reconstitution of NK cells expressing KIR3DL1 is associated with reduced NK cell activity and relapse of CML after allogeneic hematopoietic stem cell transplantation. <i>International Journal of Hematology</i> , 2020, 111, 733-738.	1.6	6
44	Role of cancer immunology in chronic myelogenous leukemia. <i>Leukemia Research</i> , 2020, 88, 106273.	0.8	19
45	Assessment of tumor volume and density as a measure of the response of advanced hepatocellular carcinoma to sorafenib: Application of automated measurements on computed tomography scans. <i>JGH Open</i> , 2020, 4, 145-152.	1.6	4
46	The non-antibiotic macrolide EM900 attenuates HDM and poly(I:C)-induced airway inflammation with inhibition of macrophages in a mouse model. <i>Inflammation Research</i> , 2020, 69, 139-151.	4.0	21
47	Clinical impact of the CONUT score in patients with multiple myeloma. <i>Annals of Hematology</i> , 2020, 99, 113-119.	1.8	30
48	&lt;p&gt;Biomarkers for Overweight in Adult-Onset Asthma&lt;p&gt;. <i>Journal of Asthma and Allergy</i> , 2020, Volume 13, 409-414.	3.4	9
49	Clinical features of Japanese patients with exacerbations of chronic obstructive pulmonary disease. <i>BMC Pulmonary Medicine</i> , 2020, 20, 318.	2.0	8
50	Surrogate Markers for Treatment-Free Remission in Patients With Chronic Myeloid Leukemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, 785-790.	0.4	3
51	Association of Genetic Polymorphisms With Afatinib-induced Diarrhoea. <i>In Vivo</i> , 2020, 34, 1415-1419.	1.3	5
52	A methotrexate-associated lymphoproliferative disorder expressing CD10 and BCL6 with the IGH/CCND1 translocation. <i>Annals of Hematology</i> , 2020, 99, 2449-2451.	1.8	3
53	Allelic polymorphisms of KIRs and antitumor immunity against chronic myeloid leukemia. <i>Immunological Medicine</i> , 2020, 44, 1-8.	2.6	7
54	Targeting aberrant DNA hypermethylation as a driver of ATL leukemogenesis by using the new oral demethylating agent OR-2100. <i>Blood</i> , 2020, 136, 871-884.	1.4	27

#	ARTICLE	IF	CITATIONS
55	Development of an application for management of drug holidays in perioperative periods. <i>Medicine (United States)</i> , 2020, 99, e20142.	1.0	4
56	Durable remission of post-transplant relapsed FLT3-ITD AML in response to gilteritinib administration after a second transplant from the same donor. <i>International Journal of Hematology</i> , 2020, 112, 249-253.	1.6	4
57	Pharmacokinetics of dasatinib in a hemodialysis patient with chronic myeloid leukemia and chronic kidney disease. <i>International Journal of Hematology</i> , 2020, 112, 115-117.	1.6	9
58	Does patient sex play a role in treatment-free remission in chronic myeloid leukemia?. <i>International Journal of Hematology</i> , 2020, 111, 903-903.	1.6	0
59	Accelerated Phase of Atypical Chronic Myeloid Leukemia with Severe Disseminated Intravascular Coagulation at Initial Presentation. <i>Internal Medicine</i> , 2020, 59, 1549-1553.	0.7	0
60	The Nonantibiotic Macrolide EM900 Attenuates House Dust Mite-Induced Airway Inflammation in a Mouse Model of Obesity-Associated Asthma. <i>International Archives of Allergy and Immunology</i> , 2020, 181, 665-674.	2.1	8
61	Origin of circulating free DNA in patients with lung cancer. <i>PLoS ONE</i> , 2020, 15, e0235611.	2.5	10
62	J-SKI will be able to elucidate whether the renal function recover or not after discontinuation of tyrosine kinase inhibitors. <i>International Journal of Hematology</i> , 2020, 112, 429-430.	1.6	0
63	Treatment-free remission after first-line dasatinib discontinuation in patients with chronic myeloid leukaemia (first-line DADI trial): a single-arm, multicentre, phase 2 trial. <i>Lancet Haematology</i> , the, 2020, 7, e218-e225.	4.6	65
64	Immune dysregulation syndrome with de novo CTLA4 germline mutation responsive to abatacept therapy. <i>International Journal of Hematology</i> , 2020, 111, 897-902.	1.6	7
65	Terminal deoxynucleotidyl transferase (TdT) negative early T cell precursor acute lymphoblastic leukemia (ETP-ALL) with spontaneous acute kidney injury. <i>Annals of Hematology</i> , 2020, 99, 885-886.	1.8	5
66	Clinical impact of advanced chronic kidney disease in patients with non-HIV pulmonary cryptococcosis. <i>BMC Pulmonary Medicine</i> , 2020, 20, 116.	2.0	2
67	Assessment of estimated glomerular filtration rate in patients with chronic myeloid leukemia following discontinuation of tyrosine kinase inhibitors. <i>International Journal of Hematology</i> , 2020, 112, 41-45.	1.6	15
68	Venue of catheter insertion does not significantly impact the event of central line-associated bloodstream infection in patients with haematological diseases. <i>Infection Prevention in Practice</i> , 2020, 2, 100050.	1.3	1
69	Phosphorylated ERK1/2 in CD4 T cells is associated with acute GVHD in allogeneic hematopoietic stem cell transplantation. <i>Blood Advances</i> , 2020, 4, 667-671.	5.2	4
70	Budget impact analysis of treatment-free remission in nilotinib-treated Japanese chronic myeloid leukemia patients. <i>Cancer Science</i> , 2020, 111, 2526-2535.	3.9	9
71	Successful Anti-TNF-Alpha Therapy for Crohn's Disease After Allogeneic Stem Cell Transplantation: A Case Report. <i>Tohoku Journal of Experimental Medicine</i> , 2020, 251, 81-85.	1.2	1
72	&lt;p&gt;First-Line Treatment with Tiotropium/Olodaterol Improves Physical Activity in Patients with Treatment-Naïve Chronic Obstructive Pulmonary Disease&lt;/p&gt;. <i>International Journal of COPD</i> , 2020, Volume 15, 2115-2126.	2.3	9

#	ARTICLE	IF	CITATIONS
73	Construction of Two Box-Like Head-and-Face Shields by Japanese Origami Folding for Use During the COVID-19 Pandemic. <i>International Journal of General Medicine</i> , 2020, Volume 13, 1669-1673.	1.8	0
74	Concomitant Nephrotic Syndrome with Diffuse Large B-cell Lymphoma: A Case Report. <i>Tohoku Journal of Experimental Medicine</i> , 2020, 252, 153-157.	1.2	1
75	Origin of circulating free DNA in patients with lung cancer. , 2020, 15, e0235611.		0
76	Origin of circulating free DNA in patients with lung cancer. , 2020, 15, e0235611.		0
77	Origin of circulating free DNA in patients with lung cancer. , 2020, 15, e0235611.		0
78	Origin of circulating free DNA in patients with lung cancer. , 2020, 15, e0235611.		0
79	Acute myeloid leukemia with t(19;21)(q13;q22) and marked eosinophilia. <i>Annals of Hematology</i> , 2019, 98, 221-222.	1.8	0
80	BCR-ABL1- and CBFβ-MYH11-positive chronic myeloid leukemia presenting with primary blast crisis and marrow fibrosis. <i>Annals of Hematology</i> , 2019, 98, 2461-2462.	1.8	1
81	Significance of FLT3-tyrosine kinase domain mutation as a prognostic factor for acute myeloid leukemia. <i>International Journal of Hematology</i> , 2019, 110, 566-574.	1.6	18
82	Discontinuation due to immune-related adverse events is a possible predictive factor for immune checkpoint inhibitors in patients with non-small cell lung cancer. <i>Thoracic Cancer</i> , 2019, 10, 1798-1804.	1.9	37
83	Mesalazine-induced airway obstruction: Utility of pulmonary function testing in drug-induced lung diseases. <i>Respiratory Investigation</i> , 2019, 57, 611-614.	1.8	2
84	Japan's high-cost medical expense benefit system could be an obstacle to promoting generic imatinib. <i>Lancet Haematology</i> , 2019, 6, e498.	4.6	2
85	Immunohistochemical localization of afatinib in male rat intestines and skin after its oral administration. <i>Acta Histochemica</i> , 2019, 121, 151439.	1.8	4
86	A new highly sensitive real-time quantitative-PCR method for detection of BCR-ABL1 to monitor minimal residual disease in chronic myeloid leukemia after discontinuation of imatinib. <i>PLoS ONE</i> , 2019, 14, e0207170.	2.5	9
87	Primary Chest Wall MYC/BCL6 Double-hit Lymphoma with t(3;7)(q27;p12) and t(8;14)(q24;q32) Translocations. <i>Internal Medicine</i> , 2019, 58, 2073-2077.	0.7	0
88	Development of a sandwich enzyme-linked immunosorbent assay for the quantification of ponatinib in serum. <i>Analytical Biochemistry</i> , 2019, 571, 14-20.	2.4	14
89	C/EBPβ is a critical mediator of IFN-γ-induced exhaustion of chronic myeloid leukemia stem cells. <i>Blood Advances</i> , 2019, 3, 476-488.	5.2	17
90	HMGCLL1 is a predictive biomarker for deep molecular response to imatinib therapy in chronic myeloid leukemia. <i>Leukemia</i> , 2019, 33, 1439-1450.	7.2	14

#	ARTICLE	IF	CITATIONS
91	Feasibility of the imatinib stop study in the Japanese clinical setting: delightedly overcome CML expert stop TKI trial (DOMEST Trial). <i>International Journal of Clinical Oncology</i> , 2019, 24, 445-453.	2.2	22
92	Epstein-Barr virus-related diffuse large B-cell lymphoma in mogamulizumab-treated adult T-cell leukemia with incomplete T-cell reconstitution. <i>International Journal of Hematology</i> , 2019, 109, 221-227.	1.6	6
93	Is clinicopathological distinction of mucosa-associated lymphoid tissue lymphoma from Waldenström macroglobulinemia essential in MYD88 L265P mutation-positive cases?. <i>International Journal of Hematology</i> , 2019, 109, 247-248.	1.6	0
94	Locally distributed multicentric plasmacytomas in the ileum secondary to lymphoma chemoimmunotherapy. <i>Annals of Hematology</i> , 2019, 98, 1501-1503.	1.8	1
95	Development of a competitive enzyme-linked immunosorbent assay for therapeutic drug monitoring of afatinib. <i>Journal of Pharmaceutical Analysis</i> , 2019, 9, 49-54.	5.3	15
96	Oral ulceration: an unusual manifestation of lymphomatoid granulomatosis. <i>Annals of Hematology</i> , 2019, 98, 1305-1307.	1.8	3
97	The MEK Inhibitor Trametinib Enhances Diverse T Cell Reconstitution with Suppressing Xenogeneic Graft-Versus-Host-Disease. <i>Blood</i> , 2019, 134, 1929-1929.	1.4	4
98	The Presence and Possible Role of Virus-Host Chimeric Transcripts in Adult T-Cell Leukemia-Lymphoma. <i>Blood</i> , 2019, 134, 2779-2779.	1.4	0
99	Anxiety and depression associated with tyrosine kinase inhibitor discontinuation in patients with chronic myeloid leukemia. <i>International Journal of Clinical Oncology</i> , 2018, 23, 974-979.	2.2	17
100	Final 3-year Results of the Dasatinib Discontinuation Trial in Patients With Chronic Myeloid Leukemia Who Received Dasatinib as a Second-line Treatment. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, 353-360.e1.	0.4	89
101	Successful treatment of post-transplant relapsed adult T cell leukemia after cord blood transplantation with low-dose, short-term lenalidomide. <i>Leukemia and Lymphoma</i> , 2018, 59, 2474-2477.	1.3	5
102	Primary effusion lymphoma-like lymphoma with a T cell phenotype. <i>Annals of Hematology</i> , 2018, 97, 717-718.	1.8	3
103	Allelic Polymorphisms of <i>KIR</i> s and <i>HLA</i> s Predict Favorable Responses to Tyrosine Kinase Inhibitors in CML. <i>Cancer Immunology Research</i> , 2018, 6, 745-754.	3.4	31
104	Relationship between the duration of trimethoprim/sulfamethoxazole treatment and the clinical outcome of pulmonary nocardiosis. <i>Respiratory Investigation</i> , 2018, 56, 166-172.	1.8	8
105	Tocilizumab for severe cytokine-release syndrome after haploidentical donor transplantation in a patient with refractory Epstein-Barr virus-positive diffuse large B-cell lymphoma. <i>Hematological Oncology</i> , 2018, 36, 324-327.	1.7	11
106	Three coexisting lymphomas in a single patient: composite lymphoma derived from a common germinal center B-cell precursor and unrelated discordant lymphoma. <i>International Journal of Hematology</i> , 2018, 107, 703-708.	1.6	5
107	Targeting of BMI-1 expression by the novel small molecule PTC596 in mantle cell lymphoma. <i>Oncotarget</i> , 2018, 9, 28547-28560.	1.8	16
108	Prognostic impact of low allelic ratio FLT3-ITD and NPM1 mutation in acute myeloid leukemia. <i>Blood Advances</i> , 2018, 2, 2744-2754.	5.2	106

#	ARTICLE	IF	CITATIONS
109	Mechanisms of acquired resistance to afatinib clarified with liquid biopsy. PLoS ONE, 2018, 13, e0209384.	2.5	25
110	Automated DNA extraction using cellulose magnetic beads can improve EGFR point mutation detection with liquid biopsy by efficiently recovering short and long DNA fragments. Oncotarget, 2018, 9, 25181-25192.	1.8	27
111	Primary Pulmonary Colloid Adenocarcinoma: How Can We Obtain a Precise Diagnosis?. Internal Medicine, 2018, 57, 3637-3641.	0.7	3
112	Sjögren Syndrome Complicated with Cystic Lung Disease and Pulmonary Amyloidosis. Case Reports in Rheumatology, 2018, 2018, 1-5.	0.6	4
113	Identification of the BRAF V600E mutation in Japanese patients with hairy cell leukemia and related diseases using a quenching probe method. International Journal of Hematology, 2018, 108, 416-422.	1.6	2
114	The Efficacy of Reduced-dose Dasatinib as a Subsequent Therapy in Patients with Chronic Myeloid Leukemia in the Chronic Phase: The LD-CML Study of the Kanto CML Study Group. Internal Medicine, 2018, 57, 17-23.	0.7	7
115	Successful Autologous Hematopoietic Stem Cell Transplantation Followed by Bortezomib Maintenance in a Patient with Relapsed CD138-low Multiple Solitary Plasmacytomas Harboring a 17p Deletion. Internal Medicine, 2018, 57, 855-860.	0.7	1
116	Current Status and Problems of T790M Detection, a Molecular Biomarker of Acquired Resistance to EGFR Tyrosine Kinase Inhibitors, with Liquid Biopsy and Re-biopsy. Anticancer Research, 2018, 38, 3559-3566.	1.1	14
117	Current state of therapeutic development for rare cancers in Japan, and proposals for improvement. Cancer Science, 2018, 109, 1731-1737.	3.9	11
118	Investigation of appropriate pre-analytical procedure for circulating free DNA from liquid biopsy. Oncotarget, 2018, 9, 31904-31914.	1.8	25
119	A case of osimertinib-resistant lung adenocarcinoma responded effectively to alternating therapy. Annals of Translational Medicine, 2018, 6, 464-464.	1.7	7
120	Aberrant Regional DNA Hypermethylation As a Preventive and Therapeutic Target for Adult T-Cell Leukemia-Lymphoma. Blood, 2018, 132, 4175-4175.	1.4	0
121	Detection of KRAS Mutations in Plasma DNA Using a fully Automated Rapid Detection System in Colorectal Cancer Patients. Pathology and Oncology Research, 2017, 23, 737-744.	1.9	3
122	5q <sup>-</sup> syndrome-like features as the first manifestation of myelodysplastic syndrome in a patient with an unbalanced whole-arm translocation der(5;19)(p10;q10). International Journal of Hematology, 2017, 105, 692-696.	1.6	1
123	Plasma T790M and HGF as potential predictive markers for EGFR-TKI re-challenge. Oncology Letters, 2017, 13, 4939-4946.	1.8	1
124	Saturated Fatty Acid Increases Lung Macrophages and Augments House Dust Mite-Induced Airway Inflammation in Mice Fed with High-Fat Diet. Inflammation, 2017, 40, 1072-1086.	3.8	61
125	Elderly Patients With Chronic Myeloid Leukemia Benefit From a Dasatinib Dose as Low as 20 mg. Clinical Lymphoma, Myeloma and Leukemia, 2017, 17, 370-374.	0.4	23
126	Mutation Profile of B-Raf Gene Analyzed by fully Automated System and Clinical Features in Japanese Melanoma Patients. Pathology and Oncology Research, 2017, 23, 181-188.	1.9	4



#	ARTICLE	IF	CITATIONS
127	Automatic digital quantification of bone marrow myeloma volume in appendicular skeletons - clinical implications and prognostic significance. <i>Scientific Reports</i> , 2017, 7, 12885.	3.3	6
128	Newly Designed Silica-Containing Redox Nanoparticles for Oral Delivery of Novel TOP2 Catalytic Inhibitor for Treating Colon Cancer. <i>Advanced Healthcare Materials</i> , 2017, 6, 1700428.	7.6	22
129	Severity and predictive factors of adverse events in pemetrexed-containing chemotherapy for non-small cell lung cancer. <i>Medical Oncology</i> , 2017, 34, 195.	2.5	7
130	Chemotherapy for primary mediastinal yolk sac tumor in a patient undergoing chronic hemodialysis: a case report. <i>Journal of Medical Case Reports</i> , 2017, 11, 43.	0.8	6
131	Pre-existing chronic interstitial pneumonia is a poor prognostic factor of Goodpasture's syndrome: a case report and review of the literature. <i>Journal of Medical Case Reports</i> , 2017, 11, 102.	0.8	4
132	Paraneoplastic Sarcoidosis in Multiple Myeloma. <i>Internal Medicine</i> , 2017, 56, 2049-2051.	0.7	7
133	Characteristics and prognosis of microscopic polyangiitis with bronchiectasis. <i>Journal of Thoracic Disease</i> , 2017, 9, 303-309.	1.4	8
134	Functional analysis of Discoidin domain receptor 2 mutation and expression in squamous cell lung cancer. <i>Lung Cancer</i> , 2017, 110, 35-41.	2.0	10
135	Dasatinib, Nilotinib, Bosutinib, Ponatinib, and Other TKIs. , 2017, , 55-75.		0
136	SPARC is a possible predictive marker for albumin-bound paclitaxel in non-small-cell lung cancer. <i>OncoTargets and Therapy</i> , 2016, Volume 9, 6663-6668.	2.0	45
137	Current status of ABL tyrosine kinase inhibitors stop studies for chronic myeloid leukemia. <i>Stem Cell Investigation</i> , 2016, 3, 36-36.	3.0	15
138	Chronic and Asymptomatic Diffuse Alveolar Haemorrhage with Microscopic Polyangiitis: A Case Report and Review of the Literature. <i>Case Reports in Rheumatology</i> , 2016, 2016, 1-6.	0.6	2
139	Clinical features of Japanese polycythemia vera and essential thrombocythemia patients harboring CALR, JAK2V617F, JAK2Ex12del, and MPLW515L/K mutations. <i>Leukemia Research</i> , 2016, 40, 68-76.	0.8	13
140	Acute myeloid leukemia with t(3;8)(q26;q24) complicated by diabetes insipidus. <i>Annals of Hematology</i> , 2016, 95, 653-655.	1.8	4
141	Combination of panobinostat with ponatinib synergistically overcomes imatinib-resistant CML cells. <i>Cancer Science</i> , 2016, 107, 1029-1038.	3.9	30
142	Monitoring EGFR T790M with plasma DNA from lung cancer patients in a prospective observational study. <i>Cancer Science</i> , 2016, 107, 162-167.	3.9	67
143	Switching to nilotinib in patients with chronic myeloid leukemia in chronic phase with molecular suboptimal response to frontline imatinib: SENSOR final results and BIM polymorphism substudy. <i>Leukemia Research</i> , 2016, 51, 11-18.	0.8	7
144	Coexistence of lung cancer and immunoglobulin G4-related lung disease in a nodule: a case report. <i>Journal of Medical Case Reports</i> , 2016, 10, 113.	0.8	16

#	ARTICLE	IF	CITATIONS
145	Specific Antileukemic Activity of PD0332991, a CDK4/6 Inhibitor, against Philadelphia Chromosome-Positive Lymphoid Leukemia. <i>Molecular Cancer Therapeutics</i> , 2016, 15, 94-105.	4.1	23
146	Rapid sensitive analysis of IDH1 mutation in lower-grade gliomas by automated genetic typing involving a quenching probe. <i>Cancer Investigation</i> , 2016, 34, 12-15.	1.3	6
147	Molecular Mechanism for Synergistic Anti-Leukemic Activity of Tyrosine Kinase Inhibitors and Glucocorticoids Against Ph+ALL. <i>Blood</i> , 2016, 128, 1059-1059.	1.4	5
148	Interleukin-33 from Monocytes Recruited to the Lung Contributes to House Dust Mite-Induced Airway Inflammation in a Mouse Model. <i>PLoS ONE</i> , 2016, 11, e0157571.	2.5	35
149	The pathophysiological significance of PPM1D and therapeutic targeting of PPM1D-mediated signaling by GSK2830371 in mantle cell lymphoma. <i>Oncotarget</i> , 2016, 7, 69625-69637.	1.8	9
150	The Pathophysiological Significance and Therapeutic Targeting of PPM1D-Mediated Signaling in Mantle Cell Lymphoma. <i>Blood</i> , 2016, 128, 2760-2760.	1.4	0
151	Torin2 Potentiates Anticancer Effects on Adult T-Cell Leukemia/Lymphoma by Inhibiting Mammalian Target of Rapamycin. <i>Anticancer Research</i> , 2016, 36, 95-102.	1.1	8
152	Preclinical activity of the novel cell-specific Moloney murine leukemia virus integration site 1 inhibitor PTC 209 in acute myeloid leukemia: Implications for leukemia therapy. <i>Cancer Science</i> , 2015, 106, 1705-1713.	3.9	27
153	Usefulness of plasma HGF level for monitoring acquired resistance to EGFR tyrosine kinase inhibitors in non-small cell lung cancer. <i>Oncology Reports</i> , 2015, 33, 391-396.	2.6	17
154	Hairy Cell Leukemia with Systemic Lymphadenopathy: Detection of BRAF Mutations in Both Lymph Node and Peripheral Blood Specimens. <i>Internal Medicine</i> , 2015, 54, 1397-1402.	0.7	4
155	Evaluation of a cloud-based local-read paradigm for imaging evaluations in oncology clinical trials for lung cancer. <i>Acta Radiologica Open</i> , 2015, 4, 205846011558810.	0.6	4
156	2-Hydroxypropyl- $\beta$ -Cyclodextrin Acts as a Novel Anticancer Agent. <i>PLoS ONE</i> , 2015, 10, e0141946.	2.5	65
157	Failure mode and effects analysis of medication adherence in patients with chronic myeloid leukemia. <i>International Journal of Clinical Oncology</i> , 2015, 20, 1203-1210.	2.2	12
158	Discontinuation of dasatinib in patients with chronic myeloid leukaemia who have maintained deep molecular response for longer than 1 year (DADI trial): a multicentre phase 2 trial. <i>Lancet Haematology</i> , 2015, 2, e528-e535.	4.6	261
159	Inhibition of HIV-1 entry by the tricyclic coumarin GUT-70 through the modification of membrane fluidity. <i>Biochemical and Biophysical Research Communications</i> , 2015, 457, 288-294.	2.1	41
160	Isopentenyl pyrophosphate secreted from Zoledronate-stimulated myeloma cells, activates the chemotaxis of T cells. <i>Biochemical and Biophysical Research Communications</i> , 2015, 463, 650-655.	2.1	15
161	Reactivation of resolved infection with the hepatitis B virus immune escape mutant G145R during dasatinib treatment for chronic myeloid leukemia. <i>International Journal of Hematology</i> , 2015, 102, 379-382.	1.6	38
162	Myeloid blast crisis in chronic myeloid leukemia with a unique deletion near the BCR/ABL breakpoint. <i>International Cancer Conference Journal</i> , 2015, 4, 26-28.	0.5	0

#	ARTICLE	IF	CITATIONS
163	Correlation between Plasma DNA and Tumor Status in an Animal Model. PLoS ONE, 2014, 9, e111881.	2.5	15
164	Efficacy of the dual PI3K and mTOR inhibitor NVP-BE235 in combination with nilotinib against BCR-ABL-positive leukemia cells involves the ABL kinase domain mutation. Cancer Biology and Therapy, 2014, 15, 207-215.	3.4	37
165	Î²2 adrenergic agonist attenuates house dust mite-induced allergic airway inflammation through dendritic cells. BMC Immunology, 2014, 15, 39.	2.2	15
166	Surface chemical approach to single-step measurement of antibody in human serum using localized surface plasmon resonance biosensor on microtiter plate system. Analytical and Bioanalytical Chemistry, 2014, 406, 4527-4533.	3.7	8
167	Ever-advancing chronic myeloid leukemia treatment. International Journal of Clinical Oncology, 2014, 19, 3-9.	2.2	29
168	ABL tyrosine kinase inhibitor-induced pulmonary alveolar proteinosis in chronic myeloid leukemia. International Journal of Hematology, 2014, 100, 611-614.	1.6	12
169	Combining the ABL1 Kinase Inhibitor Ponatinib and the Histone Deacetylase Inhibitor Vorinostat: A Potential Treatment for BCR-ABL-Positive Leukemia. PLoS ONE, 2014, 9, e89080.	2.5	15
170	Monitoring <i>EGFR</i> T790M with plasma DNA in lung cancer patients treated with EGFR tyrosine kinase inhibitor in prospective observational study.. Journal of Clinical Oncology, 2014, 32, 11014-11014.	1.6	0
171	Volume-based response evaluations with consensual lesion selection using cloud solutions in clinical trials: A pilot study.. Journal of Clinical Oncology, 2014, 32, e13538-e13538.	1.6	0
172	Î²-2 microglobulin is unsuitable as an internal reference gene for the analysis of gene expression in human colorectal cancer. Biomedical Reports, 2013, 1, 193-196.	2.0	8
173	Neuroprotective Efficacy of a New Brain-Penetrating C-Abl Inhibitor in a Murine Parkinsonâ€™s Disease Model. PLoS ONE, 2013, 8, e65129.	2.5	62
174	Metabolic Shift In Hypoxia-Adapted CML Cells and Mechanisms Of Acquired Dasatinib Resistance Uncovered By Proteomic iTRAQ Profiling. Blood, 2013, 122, 3991-3991.	1.4	1
175	Induction Of p53 Transcription and Apoptosis By XPO1 Inhibition In Mantle Cell Lymphoma. Blood, 2013, 122, 3825-3825.	1.4	0
176	Development of a Novel, Fully-Automated Genotyping System: Principle and Applications. Sensors, 2012, 12, 16614-16627.	3.8	26
177	Disseminated Nocardiosis Caused by <i>Nocardia concava</i> with Acute Respiratory Failure and Central Nervous System Involvement Treated with Linezolid. Internal Medicine, 2012, 51, 3281-3285.	0.7	7
178	Rapid automated detection of ABL kinase domain mutations in imatinib-resistant patients. Cancer Letters, 2011, 312, 228-234.	7.2	16
179	Single-step, label-free quantification of antibody in human serum for clinical applications based on localized surface plasmon resonance. Nanomedicine: Nanotechnology, Biology, and Medicine, 2011, 7, 889-895.	3.3	13
180	Lenalidomide in combination with dexamethasone induced rhabdomyolysis in a multiple myeloma patient treated with pravastatin. International Journal of Hematology, 2011, 94, 216-217.	1.6	5

#	ARTICLE	IF	CITATIONS
181	The Anti-Proliferative Effects of Hsp90 Inhibitor Tricyclic Coumarin GUT-70 and Geldanamycin Analog 17-DMAG in AML Cells in Hypoxia. <i>Blood</i> , 2011, 118, 2480-2480.	1.4	0
182	Combined Effects of a Pan-ABL1 Kinase Inhibitor, Ponatinib and Dasatinib Against T315I Mutant Forms of BCR-ABL1: In Vitro and In Vivo Studies. <i>Blood</i> , 2011, 118, 2482-2482.	1.4	0
183	Combining ABL1 Kinase Inhibitor, Ponatinib and the Histone Deacetylase (HDAC) Inhibitor Vorinostat: A Potential Treatment for BCR-ABL Positive Leukemia Cells. <i>Blood</i> , 2011, 118, 1403-1403.	1.4	0
184	Phase 1 study of INNO-406, a dual Abl/Lyn kinase inhibitor, in Philadelphia chromosome-positive leukemias after imatinib resistance or intolerance. <i>Cancer</i> , 2010, 116, 2665-2672.	4.1	45
185	Galectin-9 Overcomes Various Types of Treatment Resistance through ATF-3/Noxa Pathway-Mediated Apoptosis In Chronic Myelogenous Leukemia. <i>Blood</i> , 2010, 116, 4930-4930.	1.4	0
186	The Anti-Proliferative Effects of Tricyclic Coumarin GUT-70 as An Hsp90 Inhibitor In Mantle Cell Lymphoma. <i>Blood</i> , 2010, 116, 3977-3977.	1.4	0
187	AT-9283, a small-molecule multi-targeted kinase inhibitor for the potential treatment of cancer. <i>Current Opinion in Investigational Drugs</i> , 2010, 11, 1442-9.	2.3	5
188	Hypoxia-Adapted CML Cells Are More Primitive Population and Are Eradicated by Glyoxalase-1 Inhibitors.. <i>Blood</i> , 2009, 114, 2166-2166.	1.4	4
189	An Autophagy Inhibitor, Chloroquine, Overcomes An Imatinib-Resistant T315I Mutant of Bcr/Abl, Whose Latent May Exist Before Imatinib Treatment.. <i>Blood</i> , 2009, 114, 2183-2183.	1.4	1
190	Inhibition of Wnt/ $\beta$ -Catenin Signaling by AV65 Treatment Caused Cell Cycle Arrest and Induced Caspase-Independent or -Dependent Apoptosis in CML Cells.. <i>Blood</i> , 2009, 114, 2184-2184.	1.4	2
191	Osteoclasts Are Involved in the Maintenance of Dormant Leukemic Cells.. <i>Blood</i> , 2009, 114, 4245-4245.	1.4	1
192	AV-65, a Novel Inhibitor of the Wnt/ $\beta$ -Catenin Signaling Pathway, Inhibits the Proliferation of Myeloma Cells.. <i>Blood</i> , 2009, 114, 2866-2866.	1.4	0
193	Hepatitis B Virus Reactivation in Malignant Lymphoma with Occult HBV Carrier.. <i>Blood</i> , 2009, 114, 4794-4794.	1.4	0
194	The Tricyclic Coumarin GUT-70 Induces Apoptosis and Cell Cycle Arrest Preferentially in Mantle Cell Lymphomas with Mutant p53.. <i>Blood</i> , 2009, 114, 1684-1684.	1.4	1
195	The Efficacy of Dual PI3K and mTOR Inhibitor, NVP-BEZ235 against BCR-ABL Positive Leukemia Cells Include ABL Kinase Domain Mutation in Combination with Nilotinib.. <i>Blood</i> , 2009, 114, 3784-3784.	1.4	0
196	Combined Effects of novel Heat Shock Protein 90 Inhibitor NVP-AUY922 and Nilotinib in a Random Mutagenesis Screen.. <i>Blood</i> , 2009, 114, 3765-3765.	1.4	0
197	Galectin-9 Ameliorates Acute GVHD by Inducing T-Cell Apoptosis and Increasing Regulatory T Cell.. <i>Blood</i> , 2009, 114, 1338-1338.	1.4	0
198	Automated and Rapid Detection of BCR-ABL Kinase Domain Mutations in IM Resistant Patients with Ph+ Leukemias.. <i>Blood</i> , 2009, 114, 2590-2590.	1.4	0

#	ARTICLE	IF	CITATIONS
199	Comparison of imatinib, dasatinib, nilotinib and INNO-406 in imatinib-resistant cell lines. <i>Leukemia Research</i> , 2008, 32, 980-983.	0.8	78
200	Fully automated and super-rapid system for the detection of JAK2V617F mutation. <i>Leukemia Research</i> , 2008, 32, 1462-1467.	0.8	26
201	Abl tyrosine kinase inhibitors for overriding Bcr-Abl/T315I: from the second to third generation. <i>Expert Review of Anticancer Therapy</i> , 2008, 8, 1387-1398.	2.4	42
202	Second Generation Abl Kinase Inhibitors and Novel Compounds to Eliminate the Bcr-Abl/T315I Clone. <i>Recent Patents on Anti-Cancer Drug Discovery</i> , 2006, 1, 347-355.	1.6	4
203	Bim and Bad mediate imatinib-induced killing of Bcr/Abl+ leukemic cells, and resistance due to their loss is overcome by a BH3 mimetic. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2006, 103, 14907-14912.	7.1	310
204	NS-187, a potent and selective dual Bcr-Abl/Lyn tyrosine kinase inhibitor, is a novel agent for imatinib-resistant leukemia. <i>Blood</i> , 2005, 106, 3948-3954.	1.4	232
205	Rapid quantitation of immunoglobulin G antibodies specific for blood group antigens A and B by surface plasmon resonance. <i>Transfusion</i> , 2005, 45, 56-62.	1.6	28
206	Immune dysregulation syndrome with cytotoxic T-lymphocyte antigen 4 mutation showing multiple central nervous system lesions. <i>Clinical and Experimental Neuroimmunology</i> , 0, , .	1.0	0
207	<i>Helicobacter cinaedi</i> bacteremia in a patient with primary central nervous system lymphoma. <i>EJHaem</i> , 0, , .	1.0	0
208	Favorable HLA Polymorphisms are Associated with Lower Molecular Relapse after Tyrosine Kinase Discontinuation in Patients with Chronic Myeloid Leukemia. <i>Indian Journal of Hematology and Blood Transfusion</i> , 0, , 1.	0.6	0
209	Alveolar rhabdomyosarcoma with massive bone marrow infiltration and disseminated intravascular coagulation mimicking acute leukemia. <i>EJHaem</i> , 0, , .	1.0	0